Erdafitinib en monothérapie dans le carcinome urothélial avancé avec altération FGFR3 après au moins une ligne de traitement avec un anti-PD-1/PD-L1

IF 1.1 4区医学 Q4 ONCOLOGY

Bulletin Du Cancer Pub Date : 2025-06-01 DOI:10.1016/j.bulcan.2024.12.020

Clément Grosnon, Mathieu Jamelot

引用次数: 0

查看原文本刊更多论文

[埃尔达非替尼单药治疗fgfr3改变的晚期尿路上皮癌，此前至少有一条抗pd -1/PD-L1治疗线]。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Bulletin Du Cancer 医学-肿瘤学

CiteScore

1.90

自引率

16.70%

发文量

224

审稿时长

37 days

期刊介绍： Without doubt, the ''Bulletin du Cancer'' is the French language publication of reference in the field of cancerology. Official organ of the French Society of Cancer, this journal covers all the information available, whether in the form of original articles or review articles, but also clinical cases and letters to the editor, including various disciplines as onco-hematology, solids tumors, medical oncology, pharmacology, epidemiology, biology as well as fundamental research in cancerology. The journal proposes a clinical and therapeutic approach of high scientific standard and regular updates in knowledge are thus made possible. Articles can be submitted in French or English.